Bright Minds Biosciences (DRUG)
NASDAQ:DRUG
Want to see DRUG full AI Analyst Report?
DRUG Stock Chart & Stats
$89.90
$0.82(2.04%)
At close: 4:00 PM EST
$89.90
$0.82(2.04%)
Day’s Range― - ―
52-Week Range$23.18 - $123.75
Previous Close$40.4
Volume34.65K
Average Volume (3M)102.09K
Market Cap
$593.69M
Enterprise Value$349.13M
Total Cash (Recent Filing)$308.68M
Total Debt (Recent Filing)$81.86K
Price to Earnings (P/E)―
Beta5.27
Next Earnings
Aug 13, 2026EPS Estimate
-1.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.39
Shares Outstanding9,787,161
10 Day Avg. Volume115,326
30 Day Avg. Volume102,086
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)7.07
Price to Sales (P/S)0.00
P/FCF Ratio-66.78
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.60K
Enterprise Value/Ebitda-11.15
Forecast
1Y Price Target
$164.25Price Target Upside82.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-4.67
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet, Minimal DebtA very low debt load combined with a materially larger equity base reduces financial distress risk and preserves strategic optionality. Over the next 2–6 months this capital structure supports continued R&D spending, potential partnering flexibility, and lowers default risk versus leveraged peers.
Material Cash Reserve IncreaseA large one-time increase in cash reserves meaningfully extends near-term runway, enabling aggressive clinical investment and lowering immediate financing pressure. This liquidity supports sustained development activity and increases the company’s ability to reach value-driving milestones or negotiate deals.
Focused CNS Pipeline Targeting 5-HT ReceptorsA clear scientific focus on serotonin (5-HT) receptor biology and CNS indications concentrates expertise and assets, improving odds of program coherence and partner interest. Structural demand for better neuropsychiatric treatments makes this niche durable and attractive to collaborators and acquirers over the medium term.
Bears Say
No Revenue And Widening Net LossesPersisting zero revenue alongside materially larger losses underscores that current operations are entirely pre-revenue. That structural loss profile increases dependence on external capital and heightens execution risk: absent clear clinical readouts, financial deficits can force dilution or program prioritization decisions.
Accelerating Negative Operating Cash FlowSubstantial growth in cash burn is a durable constraint: escalating negative operating cash flow shortens runway and raises the probability of near-term financing events. Over months, this reduces strategic flexibility and may pressure management to seek dilutive financing or restrictive partnerships.
Reliance On External Financing And PartnershipsA business model dependent on capital raises and licensing exposes the company to market conditions and partner negotiation outcomes. This structural funding dependence risks dilution, delayed programs if capital is tight, and makes long-term progress contingent on successful trials or favorable deal terms.
Bright Minds Biosciences News
DRUG FAQ
What was Bright Minds Biosciences’s price range in the past 12 months?
Bright Minds Biosciences lowest stock price was $23.18 and its highest was $123.75 in the past 12 months.
What is Bright Minds Biosciences’s market cap?
Bright Minds Biosciences’s market cap is $593.69M.
When is Bright Minds Biosciences’s upcoming earnings report date?
Bright Minds Biosciences’s upcoming earnings report date is Aug 13, 2026 which is in 53 days.
How were Bright Minds Biosciences’s earnings last quarter?
Bright Minds Biosciences released its earnings results on May 19, 2026. The company reported -$0.793 earnings per share for the quarter, beating the consensus estimate of -$0.863 by $0.07.
Is Bright Minds Biosciences overvalued?
According to Wall Street analysts Bright Minds Biosciences’s price is currently Undervalued.
Does Bright Minds Biosciences pay dividends?
Bright Minds Biosciences does not currently pay dividends.
What is Bright Minds Biosciences’s EPS estimate?
Bright Minds Biosciences’s EPS estimate is -1.28.
How many shares outstanding does Bright Minds Biosciences have?
Bright Minds Biosciences has 9,787,161 shares outstanding.
What happened to Bright Minds Biosciences’s price movement after its last earnings report?
Bright Minds Biosciences reported an EPS of -$0.793 in its last earnings report, beating expectations of -$0.863. Following the earnings report the stock price went up 11.054%.
Which hedge fund is a major shareholder of Bright Minds Biosciences?
Currently, no hedge funds are holding shares in DRUG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bright Minds Biosciences
Bright Minds Biosciences Inc. is a preclinical biotechnology firm dedicated to creating serotonin-based therapies. Its primary goal is to enhance the well-being of individuals suffering from severe and life-altering conditions. The company's development pipeline includes selective agonists for the 5-HT2C, 5-HT2A, and combined 5-HT2C/A serotonin receptors, which are being explored for potential treatments in epilepsy, pain management, and neuropsychiatric disorders. Bright Minds maintains strategic collaborations with the National Institutes of Health (NIH) for epilepsy research, the University of Texas Medical Branch (UTMB) for impulse control disorders like binge eating, and the Medical College of Wisconsin. The company, incorporated in 2019, operates from its headquarters in Vancouver, Canada.
DRUG Stock 12 Month Forecast
Average Price Target
$164.25
▲(82.70% Upside)
Technical Analysis
Ownership Overview
21.09% Insiders
4.13% Mutual Funds
60.24% Other Institutional Investors
10.69% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---